Shareholder Vote

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2019 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) __________________ Delaware 1-07151 31-0595760 (State or other jurisdiction of       (Commission File Number)       (I.R.S. Employer incorporation) Identification No.) 1221 Broadway , Oakland , California 94612-1888 (Address of principal executive offices) (Zip code) ( 510 ) 271-7000 (Registrant's telephone number, including area code) Not applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: [ ]   Written communications pursuant to Rule 425 Under the Securities Act (17 CFR 230.425)   [ ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   [ ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   [ ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Name of each exchange on which registered Symbol(s) Common Stock - $1.00 par value CLX New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company      ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐ Item 5.07 Submission of Matters to a Vote of Security Holders. On November 20, 2019, The Clorox Company (the “Company”) held its annual meeting of stockholders in Pleasanton, California. The matters voted on and the results of the vote were as follows:         1.         The Company’s stockholders elected the following directors to each serve until the next Annual Meeting of Stockholders or until a successor is duly elected and qualified.   Number of Votes       For       Against       Abstain       Broker Non-Votes Amy Banse 88,139,990 569,951 218,124 21,069,742 Richard H. Carmona 85,595,295 3,093,550 239,220 21,069,742 Benno Dorer 85,233,045 3,159,541 535,479 21,069,742 Spencer C. Fleischer 87,319,078 1,330,336 278,651 21,069,742 Esther Lee 88,115,306 568,872 243,887 21,069,742 A.D. David Mackay 88,331,328 330,023 266,714 21,069,742 Robert W. Matschullat 85,735,605 2,928,324 264,136 21,069,742 Matthew J. Shattock 88,071,571 600,545 255,949 21,069,742 Pamela Thomas-Graham 85,531,713 3,169,072 227,280 21,069,742 Russell Weiner 87,791,923 879,359 256,783 21,069,742 Christopher J. Williams 88,042,111 628,369 257,585 21,069,742           2.         The Company’s stockholders voted for (on an advisory basis) the approval of the compensation of the Company’s named executive officers.           Number of Votes For       Against       Abstain       Broker Non-Votes 81,851,649 6,406,875 669,259 21,070,024           3.         The Company’s stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2020.           Number of Votes For       Against       Abstain       Broker Non-Votes 107,970,846 1,629,225 397,736 0             4.         The Company’s stockholders did not approve the proposed amendment to the Company’s Restated Certificate of Incorporation to eliminate the supermajority voting provision. Under the Company’s Restated Certificate of Incorporation, the affirmative vote of at least 80% of the outstanding voting stock is required to approve this proposal. The 87,544,878 votes in favor of this proposal represented 69.76% of the total outstanding shares of common stock.           Number of Votes For       Against       Abstain       Broker Non-Votes 87,544,878 866,508 516,679 21,069,742   SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. THE CLOROX COMPANY   Date: November 22, 2019       By:   /s/ Laura Stein Executive Vice President –       General Counsel and Corporate Affairs